drugset / Trial / NCT04169321
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
Phase 1
Completed
13 enrolled
Cytosite Biopharma Inc.
Chang Gung Memorial Hospital · collabMassachusetts General Hospital · collabUniversity of Alabama at Birmingham · collab
NaSingle-groupOpen-labelDiagnostic
Summary
First in Human Safety of \[68Ga\]-NOTA-hGZP PET Imaging in subjects with cancer undergoing treatment with a checkpoint inhibitor either as a monotherapy of in combination I-O therapy
Timeline
- Start
- 2020-06-16
- Primary completion
- 2025-03-30
- Completion
- 2025-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | \[68Ga\]-NOTA-hGZP | Diagnostic / imaging agent | 40 ug | — |